Personalized medicine
Developed by Cancer Institute NSW, the multi-data-trained tool aims to educate people over 40 about their cancer risks.
The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.
Early results show 70% accuracy of AI-assisted detection of unexplained male infertility using Asian IVF data.
The model also calculates biological ageing and survival patterns to support personalized health risk management.
The company says it is seeing an increased demand for testosterone hormone treatment.
Also, a startup from Melbourne has raised $1 million in pre-seed funding for its chemotherapy dosing AI.
The collaboration will combine AI and real-world data to accelerate oncology research and drug development.
Google will allow people to securely consolidate health data and control how it is shared.
Developed at the University of South Australia, it could help doctors safely deprescribe obsolete medications.
The round follows a $200 million seed raise earlier this year.